Loading
Life sciences · Journal article
Russian Journal of Bioorganic Chemistry · September 4, 2026
Raises a question worth testing. It does not answer one.
This is an exploratory screening study that identified pyoluteorin, a membrane-active metabolite from Pseudomonas isolates in alpaca oral microbiota, and demonstrated in vitro potentiation of polymyxin B activity against antibiotic-resistant Klebsiella pneumoniae. The work is mechanistic and preclinical; no clinical efficacy or translational data are presented.
Exploratory screening and metabolomic profiling study. Alpaca oral microbiota isolates; antibiotic-resistant Klebsiella pneumoniae strains used for testing.. Intervention: Pyoluteorin at concentrations including 1.5 μg/mL, combined with polymyxin B.. Compared with: Pyoluteorin alone; polymyxin B alone (implied)..
Pyoluteorin at sub-cytotoxic concentration 1.5 μg/mL (IC50 = 2.0 ± 0.3 μg/mL) enhanced polymyxin B susceptibility of antibiotic-resistant Klebsiella pneumoniae by an order of magnitude Pyoluteorin alone exhibited limited antimicrobial efficacy but strongly potentiated clinically relevant antibiotics
No animal model, toxicology, or pharmacokinetic data provided.
This is a preclinical discovery with no direct clinical application yet. The concept of using membrane-active adjuvants to sensitize resistant pathogens is mechanistically interesting but requires translational validation before consideration for therapeutic development.
This is a mechanistic screening study identifying a microbial metabolite and its in vitro antimicrobial properties; it raises a question about potential therapeutic synergy rather than testing an intervention in a clinical or translational trial.
As stated by the source record.
Quoted from the source exactly as published.
This is a preclinical discovery with no direct clinical application yet. The concept of using membrane-active adjuvants to sensitize resistant pathogens is mechanistically interesting but requires translational validation before consideration for therapeutic development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Objective: The animal oral microbiota represents a promising reservoir of microorganisms that produce antimicrobial metabolites and compounds capable of modulating bacterial antibiotic sensitivity. Here, we aimed to screen the oral microbiota of alpacas to identify microbial strains exhibiting antimicrobial activity against Gram-negative and Gram-positive bacteria, fungi, and yeasts. Methods: To dissect the underlying antimicrobial mechanisms, we selected Pseudomonas isolates that displayed targeted activity against Gram-negative bacteria and subjected them to metabolomic profiling. Results and Discussion: The analysis revealed that this antimicrobial activity is driven by the production of pyoluteorin, a membrane-active metabolite. Although pyoluteorin alone exhibited limited antimicrobial efficacy, it strongly potentiated the action of clinically relevant antibiotics. Notably, at a sub-cytotoxic concentration of 1.5 μg/mL (IC50 = 2.0 ± 0.3 μg/mL), pyoluteorin sensitized antibiotic-resistant Klebsiella pneumoniae strains, enhancing their susceptibility to the membrane-disrupting antibiotic polymyxin B by an order of magnitude. Conclusions: The future development of bacterio-selective membrane-active agents will facilitate the deployment of such synergistic approaches for the emergency treatment of infectious diseases caused by multidrug-resistant pathogens.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.